Med. praxi. 2021;18(1):22-28

Simultaneous intervention for arterial hypertension and dyslipidaemia

MUDr. Eva Tůmová, Ph.D.
Centrum preventivní kardiologie, 3. interní klinika 1. LF UK a VFN v Praze

Arterial hypertension and dyslipidaemia are two widespread risk factors of cardiovascular diseases that can be well managed pharmacologically. They often co-occur, even in relatively young individuals in whom it is necessary to carry out a targeted search for all risk factors and initiate their management early. Particularly in younger age groups, this is associated with inadequate compliance that can be improved by proper doctor-patient communication, ranging from explaining the cardiovascular risk to the patient to describing a positive effect of the proposed long-term treatment to choosing, if possible, a fixed combination of drugs which is known to improve adherence to pharmacotherapy.

Keywords: cardiovascular risk factors, arterial hypertension, dyslipidaemia, primary prevention.

Published: April 6, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tůmová E. Simultaneous intervention for arterial hypertension and dyslipidaemia. Med. praxi. 2021;18(1):22-28.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rozvoj technologické platformy NZIS. Zdravotnická ročenka České republiky 2018. ÚZIS. Dostupné z WWW: .
    2. Chmelík Z, Vrablík M, Vaclová M, Lánská V. Vysoká prevalence kardiovaskulárnîch rizikových faktorů a neuspokojivá kontrola hladin LDL-cholesterolu v populaci 40letých mužů a 50letých žen v České republice. AtheroRev 2016; 1(3): 111-115.
    3. Ference BA, Bhatt DL, Catapano AL, et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019; 322(14): 1381-1391. Go to original source... Go to PubMed...
    4. Ference BA, Cannon CP, Landmesser U, et al. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein invertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: ananalysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur Heart J. 2017; European Heart Journal. 2018; 39: 2540-2545. Go to original source... Go to PubMed...
    5. Gupta A, Mackay J, Whitehouse A, et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patiens with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial [Publisher correction appears in Lancet. 2018; 392(10156): 1402]. Lancet. 2018; 392(10153): 1127-1137. Go to original source... Go to PubMed...
    6. Ford I, Murray H, McCowan C, Packard CJ. Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study. Circulation. 2016; 133(11): 1073-1080. Go to original source... Go to PubMed...
    7. Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation. 2010; 121(4): 586-613. Go to original source... Go to PubMed...
    8. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005; 165(10): 2-22. Go to original source... Go to PubMed...
    9. Widimský J Jr, Filipovský J, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2017. Doporučení České společnosti pro hypertenzi. Hypertenze KV Prevence 2018; 7(Suppl): 2-22.
    10. Vrablík M, Piťha J, Bláha V, et al. Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2019. AtheroRev 2019; 4(3): 126-137. Go to original source...
    11. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55(2): 399-407. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.